Avacta Group Plc (AVCTF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Avacta Group Plc (AVCTF) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. Calificado con 47/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 17 mar 2026Avacta Group Plc (AVCTF) Resumen de Asistencia Médica y Tuberías
Avacta Group Plc is a clinical-stage biopharmaceutical company developing cancer therapies and diagnostics using its proprietary Affimer and pre|CISION platforms. With operations in the UK, North America, and Asia, Avacta focuses on novel immunotherapies and diagnostic assays, differentiating itself through research collaborations and strategic partnerships.
Tesis de Inversión
Avacta Group Plc presents a compelling, albeit high-risk, investment opportunity within the biotechnology sector. The company's proprietary Affimer and pre|CISION platforms offer potential for developing novel cancer therapies and diagnostics. Key value drivers include the advancement of its therapeutic pipeline through clinical trials and the expansion of its diagnostic product offerings. The partnerships with LG Chem, POINT Biopharma, and AffyXell represent significant growth catalysts. However, the company's negative profit margin of -30398.2% and gross margin of -1217.9% highlight the financial risks associated with investing in a clinical-stage biopharmaceutical company. Successful clinical trial outcomes and regulatory approvals are critical for realizing the company's long-term potential. Investors should closely monitor the progress of Avacta's clinical programs and its ability to secure additional funding to support its research and development activities.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $0.42 billion indicates a relatively small but potentially high-growth company.
- Negative P/E ratio of -15.90 reflects the company's current lack of profitability, typical for clinical-stage biopharmaceutical companies.
- Profit margin of -30398.2% highlights the significant expenses associated with research and development in the biotechnology industry.
- Gross margin of -1217.9% indicates that the cost of goods sold exceeds revenue, requiring substantial external funding.
- Beta of -0.24 suggests that the stock price is less volatile than the overall market.
Competidores y Pares
Fortalezas
- Proprietary Affimer and pre|CISION platforms.
- Strategic partnerships with leading pharmaceutical companies.
- Clinical-stage pipeline of novel cancer therapies.
- Experienced management team.
Debilidades
- Negative profit margin and gross margin.
- High research and development costs.
- Reliance on external funding.
- Limited commercialized products.
Catalizadores
- Upcoming: Clinical trial results for lead therapeutic candidates expected in the next 12-18 months.
- Ongoing: Expansion of strategic partnerships and licensing agreements.
- Ongoing: Development of novel diagnostic assays based on the Affimer platform.
- Ongoing: Application of pre|CISION technology to new chemotherapy drugs.
Riesgos
- Potential: Clinical trial failures could negatively impact the company's stock price.
- Potential: Regulatory hurdles and lengthy approval processes could delay the commercialization of its products.
- Ongoing: Competition from other biotechnology companies could erode market share.
- Ongoing: Economic downturn and reduced funding for research and development could limit the company's growth.
Oportunidades de crecimiento
- Expansion of Therapeutic Pipeline: Avacta has the opportunity to expand its therapeutic pipeline by advancing its current programs through clinical trials and developing new therapies based on its Affimer and pre|CISION platforms. The market for cancer therapies is projected to reach $200 billion by 2028, offering significant revenue potential. Successful clinical trial outcomes and regulatory approvals are critical milestones for realizing this opportunity. Timeline: Ongoing, with clinical trial results expected in the next 12-24 months.
- Strategic Partnerships and Licensing Agreements: Avacta can leverage strategic partnerships and licensing agreements to accelerate the development and commercialization of its technologies. The partnership with POINT Biopharma for tumor-activated radiopharmaceuticals demonstrates this approach. Expanding these collaborations can provide access to new markets, technologies, and funding. Timeline: Ongoing, with potential for new partnerships in the next 6-12 months.
- Development of Novel Diagnostic Assays: Avacta's Affimer platform can be used to develop novel diagnostic assays for a wide range of diseases. The company's AffiDX SARS-CoV-2 lateral flow rapid antigen test demonstrates the potential of this platform. Expanding the diagnostic product line can generate revenue and establish Avacta as a leader in the diagnostics market. Timeline: Ongoing, with potential for new product launches in the next 12-18 months.
- Application of pre|CISION Technology: The pre|CISION platform offers the potential to selectively activate chemotherapy drugs in the tumor microenvironment, reducing systemic toxicity. This technology can be applied to a wide range of chemotherapy drugs, offering a significant advantage over traditional chemotherapy. Further development and validation of this technology can lead to new and improved cancer therapies. Timeline: Ongoing, with preclinical and clinical studies planned for the next 12-24 months.
- Expansion into New Geographic Markets: Avacta can expand its geographic reach by entering new markets in Asia and Europe. The company already has operations in the United Kingdom, North America, and South Korea. Expanding into new markets can increase revenue and diversify the company's geographic risk. Timeline: Ongoing, with potential for expansion into new markets in the next 24-36 months.
Oportunidades
- Expansion of therapeutic pipeline through clinical trials.
- Development of novel diagnostic assays.
- Application of pre|CISION technology to new chemotherapy drugs.
- Expansion into new geographic markets.
Amenazas
- Competition from other biotechnology companies.
- Regulatory hurdles and lengthy approval processes.
- Clinical trial failures.
- Economic downturn and reduced funding for research and development.
Ventajas competitivas
- Proprietary Affimer and pre|CISION platforms provide a technological advantage.
- Strategic partnerships with leading pharmaceutical and diagnostic companies.
- Strong intellectual property portfolio protects its technologies.
- Clinical-stage pipeline of novel cancer therapies.
Acerca de AVCTF
Avacta Group Plc, established in 2003 and based in Wetherby, United Kingdom, is a clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies and diagnostics. The company's core technologies are its proprietary Affimer and pre|CISION platforms. The Affimer platform is used to develop custom Affimer proteins for customer products and in-house diagnostic assays, including the AffiDX SARS-CoV-2 lateral flow rapid antigen tests. The pre|CISION platform is designed to selectively activate chemotherapy drugs in the tumor microenvironment, reducing systemic toxicity. Avacta operates through two segments: Diagnostics and Therapeutics. Its therapeutic pipeline focuses on novel cancer immunotherapies, combining its proprietary platforms to target and treat tumors more effectively. The company has established several strategic collaborations, including a research collaboration with pre|CISION technology incorporating a substrate sensitive to fibroblast activation protein alpha, a drug development collaboration with LG Chem Life Sciences, a partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies, a licensing agreement with POINT Biopharma Inc. for the development of tumor-activated radiopharmaceuticals, and a drug development partnership with AffyXell to develop engineered mesenchymal stem cells for autoimmune diseases. Avacta's geographic reach extends across the United Kingdom, North America, South Korea, and the rest of Asia and Europe.
Qué hacen
- Develops cancer therapies based on its Affimer and pre|CISION platforms.
- Creates diagnostic assays for various diseases.
- Develops custom Affimer proteins for customer products.
- Offers AffiDX SARS-CoV-2 lateral flow rapid antigen tests.
- Creates novel cancer immunotherapies.
- Partners with other companies for drug development and research.
Modelo de Negocio
- Develops and commercializes cancer therapies and diagnostic assays.
- Generates revenue through product sales and licensing agreements.
- Collaborates with other companies for research and development.
- Out-licenses its Affimer and pre|CISION platforms to third parties.
Contexto de la Industria
Avacta Group Plc operates in the biotechnology industry, a sector characterized by intense competition, high research and development costs, and lengthy regulatory approval processes. The market for cancer therapies and diagnostics is substantial and growing, driven by an aging population and increasing incidence of cancer. Key trends in the industry include the development of personalized medicine, immunotherapies, and targeted drug delivery systems. Avacta's Affimer and pre|CISION platforms position it to capitalize on these trends. Competitors include companies such as BOVNF, CLVLY, CMVLF, CRLBF, and HLOSF, each pursuing different approaches to cancer treatment and diagnostics.
Clientes Clave
- Pharmaceutical companies seeking novel drug targets and therapies.
- Diagnostic companies looking for innovative diagnostic assays.
- Research institutions conducting research on cancer and other diseases.
- Patients in need of effective cancer therapies and diagnostic tests.
Finanzas
Gráfico e información
Precio de la acción de Avacta Group Plc (AVCTF): Price data unavailable
Últimas noticias
-
With 75% institutional ownership, Avacta Group Plc (LON:AVCT) is a favorite amongst the big guns
Simply Wall St. · 15 feb 2026
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para AVCTF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para AVCTF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de AVCTF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Christina Marie Coughlin
CEO
Christina Marie Coughlin serves as the CEO of Avacta Group Plc. Her background includes extensive experience in the biopharmaceutical industry, with a focus on oncology and drug development. She has held leadership positions at various pharmaceutical companies, contributing to the development and commercialization of several successful therapies. Her expertise spans clinical development, regulatory affairs, and commercial strategy. She brings a wealth of knowledge and a proven track record to Avacta.
Historial: Since assuming the role of CEO, Christina Marie Coughlin has focused on advancing Avacta's clinical programs and expanding its strategic partnerships. Key milestones under her leadership include the progression of the therapeutic pipeline through clinical trials and the establishment of collaborations with LG Chem, POINT Biopharma, and AffyXell. She has also overseen the development of novel diagnostic assays and the expansion of the company's geographic reach.
Información del mercado OTC de AVCTF
The OTC Other tier represents the lowest tier of the OTC market, indicating that Avacta Group Plc may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial information available and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited liquidity and transparency.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure increases the risk of investing in AVCTF.
- Lower liquidity compared to major exchanges can lead to price volatility.
- OTC Other tier stocks may be subject to less regulatory oversight.
- The company's ability to meet future financial obligations is uncertain.
- Potential for delisting or suspension from the OTC market.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property portfolio.
- Review the company's clinical trial results and regulatory approvals.
- Monitor the company's cash flow and financial stability.
- Consult with a financial advisor before investing.
- The company's proprietary Affimer and pre|CISION platforms.
- Strategic partnerships with leading pharmaceutical companies.
- Clinical-stage pipeline of novel cancer therapies.
- Experienced management team.
Preguntas Comunes Sobre AVCTF
¿Cuáles son los factores clave para evaluar AVCTF?
Avacta Group Plc (AVCTF) actualmente tiene una puntuación IA de 47/100, indicando puntuación baja. Fortaleza clave: Proprietary Affimer and pre|CISION platforms.. Riesgo principal a monitorear: Potential: Clinical trial failures could negatively impact the company's stock price.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de AVCTF?
AVCTF actualmente puntúa 47/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de AVCTF?
Los precios de AVCTF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre AVCTF?
La cobertura de analistas para AVCTF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en AVCTF?
Las categorías de riesgo para AVCTF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Clinical trial failures could negatively impact the company's stock price.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de AVCTF?
La relación P/E para AVCTF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está AVCTF sobrevalorada o infravalorada?
Determinar si Avacta Group Plc (AVCTF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de AVCTF?
Avacta Group Plc (AVCTF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change.
- OTC stocks carry additional risks due to limited disclosure and liquidity.